



PCT/EP200 4 / 0 1 3 0 7 2



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport

South Wales
NP10 8QQ

EPO - DG 1

24. 12. 2004

12 JAN 2005

WIPO

PCT


98

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 8 December 2004

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Patent Form 1/77
(Rule 16)

**The
Patent
Office**

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your Reference **SAL/PB60581P** **20NOV03 E853518-1 D02029**
P01/7700 0.00-0326963.6

2. Patent application number
(The Patent office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LIMITED
GLAXO WELLCOME HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX
UB6 ONN
GB

00473587003

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

GB

19 NOV 2003 0326963.6

4 Title of the invention **COMPOUNDS**

5 Name of your agent (if you have one) **STEPHANIE A. LEAROYD**

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY
980 GREAT WEST ROAD
BRENTFORD, MIDDLESEX
TW8 9GS, GB

Patents ADP number (if you know it)

08082091002

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months

Country	Priority application number (if you know it)	Date of Filing (day / month / year)
---------	--	-------------------------------------

7. Divisionals: etc Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application	Date of filing (day / month / year)
----------------------------------	-------------------------------------

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? **YES**

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Otherwise answer NO See note (d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheet of this form

Description 45

Claim(s) 4

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patent Form 9/77)

Request for substantive examination (Patent Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

STEPHANIE A. LEAROYD

Signature(s)

Date: 19 NOVEMBER 2003

12. Name and daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

COMPOUNDS

BACKGROUND OF THE INVENTION

The present invention relates to isoquinoline derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such isoquinoline derivatives are useful in the treatment of diseases associated with inappropriate ALK5 activity.

An important large family of enzymes is the protein kinase enzyme family. Currently, there are about 500 different known protein kinases. However, because three to four percent of the human genome is a code for the formation of protein kinases, there may be many thousands of distinct and separate kinases in the human body. Protein kinases serve to catalyze the phosphorylation of an amino acid side chain in various proteins by the transfer of the γ -phosphate of the ATP-Mg²⁺ complex to said amino acid side chain. These enzymes control the majority of the signaling processes inside cells, thereby governing cell function, growth, differentiation and destruction (apoptosis) through reversible phosphorylation of the hydroxyl groups of serine, threonine and tyrosine residues in proteins. Studies have shown that protein kinases are key regulators of many cell functions, including signal transduction, transcriptional regulation, cell motility, and cell division. Several oncogenes have also been shown to encode protein kinases, suggesting that kinases play a role in oncogenesis. These processes are highly regulated, often by complex intermeshed pathways where each kinase will itself be regulated by one or more kinases. Consequently, aberrant or inappropriate protein kinase activity can contribute to the rise of disease states associated with such aberrant kinase activity. Due to their physiological relevance, variety and ubiquitousness, protein kinases have become one of the most important and widely studied family of enzymes in biochemical and medical research.

The protein kinase family of enzymes is typically classified into two main subfamilies: Protein Tyrosine Kinases and Protein Serine/Threonine Kinases, based on the amino acid residue they phosphorylate. The serine/threonine kinases (PSTK), includes cyclic AMP- and cyclic GMP-dependent protein kinases, calcium and phospholipid dependent protein kinase, calcium- and calmodulin-dependent protein kinases, casein kinases, cell division cycle protein kinases and others. These kinases are usually cytoplasmic or associated with the

particulate fractions of cells, possibly by anchoring proteins. Aberrant protein serine/threonine kinase activity has been implicated or is suspected in a number of pathologies such as rheumatoid arthritis, psoriasis, septic shock, bone loss, many cancers and other proliferative diseases. Accordingly, serine/threonine kinases and the signal transduction pathways which they are part of are important targets for drug design. The tyrosine kinases phosphorylate tyrosine residues. Tyrosine kinases play an equally important role in cell regulation. These kinases include several receptors for molecules such as growth factors and hormones, including epidermal growth factor receptor, insulin receptor, platelet derived growth factor receptor and others. Studies have indicated that many tyrosine kinases are transmembrane proteins with their receptor domains located on the outside of the cell and their kinase domains on the inside. Much work is also under progress to identify modulators of tyrosine kinases as well.

TGF- β 1 is the prototypic member of a family of cytokines including the TGF- β s, activins, inhibins, bone morphogenetic proteins and Müllerian-inhibiting substance, that signal through a family of single transmembrane serine/threonine kinase receptors. These receptors can be divided in two classes, the type I or activin like kinase (ALK) receptors and type II receptors. The ALK receptors are distinguished from the type II receptors in that the ALK receptors (a) lack the serine/threonine rich intracellular tail, (b) possess serine/threonine kinase domains that are very homologous between type I receptors, and (c) share a common sequence motif called the GS domain, consisting of a region rich in glycine and serine residues. The GS domain is at the amino terminal end of the intracellular kinase domain and is critical for activation by the type II receptor. Several studies have shown that TGF- β signaling requires both the ALK and type II receptors. Specifically, the type II receptor phosphorylates the GS domain of the type I receptor for TGF- β , ALK5, in the presence of TGF- β . The ALK5, in turn, phosphorylates the cytoplasmic proteins smad2 and smad3 at two carboxy terminal serines. The phosphorylated smad proteins translocate into the nucleus and activate genes that contribute to the production of extracellular matrix..

Activation of the TGF- β 1 axis and expansion of extracellular matrix are early and persistent contributors to the development and progression of chronic renal disease and vascular disease. Border W.A., et al, *N. Engl. J. Med.*, 1994; 331(19), 1286-92. Further, TGF- β 1 plays

a role in the formation of fibronectin and plasminogen activator inhibitor-1, components of sclerotic deposits, through the action of smad3 phosphorylation by the TGF- β 1 receptor ALK5. Zhang Y., *et al*, *Nature*, 1998; 394(6696), 909-13; Usui T., *et al*, *Invest. Ophthalmol. Vis. Sci.*, 1998; 39(11), 1981-9.


Progressive fibrosis in the kidney and cardiovascular system is a major cause of suffering and death and an important contributor to the cost of health care. TGF- β 1 has been implicated in many renal fibrotic disorders. Border W.A., *et al*, *N. Engl. J. Med.*, 1994; 331(19), 1286-92. TGF- β 1 is elevated in acute and chronic glomerulonephritis Yoshioka K., *et al*, *Lab. Invest.*, 1993; 68(2), 154-63, diabetic nephropathy Yamamoto, T., *et al*, 1993, *PNAS* 90, 1814-1818., allograft rejection, HIV nephropathy and angiotensin-induced nephropathy Border W.A., *et al*, *N. Engl. J. Med.*, 1994; 331(19), 1286-92. In these diseases the levels of TGF- β 1 expression coincide with the production of extracellular matrix. Three lines of evidence suggest a causal relationship between TGF- β 1 and the production of matrix. First, normal glomeruli, mesangial cells and non-renal cells can be induced to produce extracellular-matrix protein and inhibit protease activity by exogenous TGF- β 1 in vitro. Second, neutralizing anti-bodies against TGF- β 1 can prevent the accumulation of extracellular matrix in nephritic rats. Third, TGF- β 1 transgenic mice or in vivo transfection of the TGF- β 1 gene into normal rat kidneys resulted in the rapid development of glomerulosclerosis. Kopp J.B., *et al*, *Lab. Invest.*, 1996; 74(6), 991-1003. Thus, inhibition of TGF- β 1 activity is indicated as a therapeutic intervention in chronic renal disease.

The present inventors have discovered novel isoquinoline compounds, which are inhibitors of kinase activity, in particular ALK5 activity. Such isoquinoline derivatives are useful in the treatment of disorders associated with inappropriate kinase, more particularly inappropriate ALK5 activity, in particular in the treatment and prevention of various disease states mediated by ALK5 kinase mechanisms, such as chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to

lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

BRIEF SUMMARY OF THE INVENTION

In one aspect of the present invention, there is provided a compound of Formula (I):



wherein R¹ represents a phenyl or naphthyl group (each of which is optionally substituted by one or more substituents selected from -OH, -C₁₋₆alkyl, C₁₋₆haloalkyl, -C₁₋₆alkoxy, -halogen,), or a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by -C₁₋₆alkoxy, -C₁₋₆alkyl, C₁₋₆haloalkyl or =O;

R² represents H, phenyl (optionally substituted by -NR³R⁴, -C₁₋₄alkoxy, -C₁₋₆alkyl, -CONR³R⁴, -SO₂NR³R⁴, -NHCONR³R⁴, -NHCOC₁₋₆alkyl, -C₁₋₆haloalkyl, -OCH₂-O-, -phenoxy (wherein the phenyl moiety is optionally substituted by NH₂, -C₁₋₃alkyl, -C₁₋₃alkoxy, -CF₃, -5 membered heteroaryl group comprising one or two nitrogen atoms), a -benzoimidazolyl, a -benzothiazolyl, or an -isoquinoliny, or quinoliny group;

R³ and R⁴ are independently selected from H, -C₁₋₆alkyl, -C₁₋₃alkylNR⁵R⁶;

R⁵ and R⁶ are independently H or C₁₋₃alkyl;

or a salt, solvate, or physiologically functional derivative thereof:

In a second aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a salt,

solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

In a third aspect of the present invention, there is provided a compound of formula (I), or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

In a fourth aspect of the present invention, there is provided a method of treating a disorder in a mammal, said disorder being mediated by inappropriate ALK5 activity, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I) or a salt, solvate or a physiologically functional derivative thereof.

In a fifth aspect of the present invention, there is provided the use of a compound of formula (I), or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate ALK5 activity.

In a sixth aspect there is provided a method of treating chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) or a salt, solvate or a physiologically functional derivative thereof.

In a seventh aspect there is provided a compound of formula (I) or a salt, solvate or physiologically functional derivative thereof in the manufacture of a medicament for the treatment of chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major

component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

5 DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

15 As used herein the term "alkyl" refers to a straight- or branched-chain hydrocarbon radical having the specified number of carbon atoms, so for example as used herein, the terms "C₁-C₃ alkyl" and "C₁-C₆ alkyl" refer to an alkyl group, as defined above, containing at least 1, and at most 3 or 6 carbon atoms respectively. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, n-hexyl and the like.

As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term "halo" refers to the halogen radicals: fluoro (-F), chloro (-Cl), bromo(-Br), and iodo(-I).

25 As used herein, the term "C₁-C₆ haloalkyl" refers to an alkyl group as defined above containing the specified number of 6 carbon atoms respectively substituted with at least one halo group, halo being as defined herein. Examples of such branched or straight chained haloalkyl groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more halos, e.g., fluoro, chloro, bromo and iodo.

As used herein, the term "heteroaryl" refers to a monocyclic five to seven membered aromatic ring, or to a fused bicyclic aromatic ring system comprising two of such monocyclic five to seven membered aromatic rings. These heteroaryl rings contain one, two or three nitrogen heteroatoms. Examples of "heteroaryl" groups used herein include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyridazyl, pyrazinyl, pyrimidyl, quinolinyl, isoquinolinyl, indolyl, indazolyl. The term "5 membered heteroaryl comprising one or two nitrogen atoms" includes pyrrolyl, imidazolyl, pyrazolyl.

As used herein, the term "alkoxy" refers to the group R_aO- , where R_a is alkyl as defined above and the terms "C₁-C₄ alkoxy" and "C₁-C₆ alkoxy" refer to an alkoxy group as defined herein wherein the alkyl moiety contains at least 1, and at most 4 or 6, carbon atoms. Exemplary "C₁-C₃ alkoxy" and "C₁-C₆ alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and t-butoxy.

As used herein, the term "haloalkoxy" refers to the group R_aO- , where R_a is haloalkyl as defined above and the term "C₁-C₆ haloalkoxy" refers to a haloalkoxy group as defined herein wherein the haloalkyl moiety contains at least 1, and at most 6, carbon atoms. Exemplary C₁-C₆ haloalkoxy groups useful in the present invention include, but is not limited to, trifluoromethoxy.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.

As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing, (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.

As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid. Most preferably the solvent used is water.

10 The term "ALK5 inhibitor" is used to mean a compound which inhibits the ALK5 receptor.

The term "ALK5 mediated disease" or a "disorders or diseases mediated by inappropriate ALK5 activity" is used to mean any disease state mediated or modulated by ALK5, kinase mechanisms, in particular chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

25 Preferably R^1 is phenyl (optionally substituted by one or more substituents selected from $-OCH_2OCH_3$, $-OH$, $-halogen$, $-OCH_3$), naphthyl (substituted by OH), indolyl, quinolyl or a pyridinyl moiety (wherein the pyridinyl moiety is optionally substituted by $-OCH_3$ or $=O$).

More preferably R^1 is phenyl substituted by OH . Particularly the OH is on the 5 position of the phenyl ring.

Preferably R^2 is H , quinolyl, phenyl (optionally substituted by $-SO_2NH_2$, CF_3 , $-CONH_2$, $-imidazolyl$, $-OCH_3$, C_{1-3} alkyl, $-OCH_2O-$, $CONHCH_2CH_2N(CH_2CH_3)$, $-O-phenyl$ (where the

phenyl is substituted by -NH₂), -NHCOCH₃, -NH₂, -NHCOCH₃) or benzoimidazolyl or benzothiazolyl moiety.

More preferably R² is a quinoliny moiety, particularly a quinoline 6-yl moiety.

While the preferred groups for each variable have generally been listed above separately for each variable, preferred compounds of this invention include those in which several or each variable in Formula (1) is selected from the preferred, more preferred, or most preferred groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more preferred, and most preferred groups.

Specific examples of compounds of the present invention include:

5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;

15 5-(2-Methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;

5-(Pyridin-2-on-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;

5-(4-Methoxymethoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

5-(4-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

20 1-Amino-5-(indol-5-yl)isoquinoline;

1-Amino-5-(2-methoxypyridin-5-yl)isoquinoline;

1-Amino-5-(pyridin-2-on-5-yl)isoquinoline;

1-Amino-5-(3-methoxyphenyl)isoquinoline;

5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline;

25 5-(4-Chloro-3-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline;

5-(3-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

1-(4-Aminocarbonylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

30 5-(3-Hydroxyphenyl)-1-[4-(imidazol-1-yl)phenyl]aminoisoquinoline;

3-[5-(3-Hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(3-methoxyphenyl)aminoisoquinoline;

1-(3-Ethylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

N-(2-Diethylaminoethyl)-4-[5-(3-hydroxyphenyl)isoquinolin-1-ylamino]benzamide;

1-(3-(4-Aminophenoxy)phenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

5-(3-Hydroxyphenyl)-1-phenylaminoisoquinoline;

5-(3-Hydroxyphenyl)-1-(3,4-methylenedioxyphenyl)aminoisoquinoline;

5 1-Amino-5-(3-hydroxyphenyl)isoquinoline;

1-(Benzothiazol-6-yl)amino-5-(3-hydroxyphenyl)isoquinoline

1-(Benzimidazol-5-yl)amino-5-(3-hydroxyphenyl)isoquinoline

1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline

{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}urea

10 N-{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide;

It is to be understood that reference to compounds of formula (I) above, following herein, refers to compounds within the scope of formula (I) as defined above with respect to R¹, R², R³, R⁴, R⁵ and R⁶ unless specifically limited otherwise.

15

The present invention also covers salt of the compounds of formula (I). Typically, the salts of the present invention are pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Suitable salts according to the invention include those formed with both
 20 organic and inorganic acids and bases. Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride,
 25 hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, potassium, salicylate, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide,
 30 trimethylammonium and valerate. Other salts, which are not pharmaceutically acceptable, may be useful in the preparation of compounds of this invention and these form a further aspect of the invention.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will be readily understood that they are each preferably provided in substantially pure form, for example, at least 60% pure, more suitably at least 75% pure and preferably at least 85% pure, especially at least 98% pure (% in a weight for weight basis).

5

While it is possible that, for use in therapy, therapeutically effective amounts of a compound of formula (I), as well as salts, solvates and physiological functional derivatives thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the invention further provides
10 pharmaceutical compositions, which include therapeutically effective amounts of compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, are as described above. The carrier(s), diluent(s) or excipient(s) must be acceptable
15 in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I), or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers,
20 diluents or excipients.

25

Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5mg to 1g, preferably 1mg to 700mg, more preferably 5mg to 100mg of a
25 compound of the formula (I), depending on the condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an
30 active ingredient. Furthermore, such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art.

Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl

cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such

5 as carboxymethylcellulose, an alginic acid, gelatin, or polyvinyl pyrrolidone; a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an
10 alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert
15 carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

20 Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as
25 ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be
30 microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

The compounds of formula (I), and salts, solvates and physiological functional derivatives thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with

soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).

Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.

Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.

Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

25

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier,

30

for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. However, an effective amount of a compound of formula (I) for the treatment of diseases associated with inappropriate ALK5 activity, will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula (I) *per se*. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.

The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof, are believed to have utility in chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis as a result of inhibition of the protein kinase ALK5.

The present invention thus also provides compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof, or physiologically functional derivatives thereof, for use in medical therapy, and particularly in the treatment of disorders mediated by ALK5 activity.

The inappropriate ALK5 activity referred to herein is any ALK5 activity that deviates from the normal ALK5 activity expected in a particular mammalian subject. Inappropriate ALK5 activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of ALK5 activity. Such inappropriate activity may result then, for example, from over expression or mutation of the protein kinase leading to inappropriate or uncontrolled activation

The present invention is directed to methods of regulating, modulating, or inhibiting ALK5 for the prevention and/or treatment of disorders related to unregulated ALK5 activity. In particular, the compounds of the present invention can also be used in the treatment of various disease states mediated by ALK5 kinase mechanisms, including chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

A further aspect of the invention provides a method of treatment of a mammal suffering from a disorder mediated by ALK5 activity, which includes administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof. In a preferred embodiment, the disorder is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major

component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

5 A further aspect of the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of a disorder characterized by ALK5 activity, in particular, chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive
10 heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

15

The compound of formula (1) for use in the instant invention and their salts, solvates and physiologically functional derivatives thereof may be used in combination with one or more other therapeutic agents. The invention thus provides in a further aspect the use of a combination comprising a compound of formula (1) with a further therapeutic agent or
20 agents in the treatment of diseases associated with inappropriate ALK5 activity.

When the compounds of formula (1) are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

25

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components
30 of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

When a compound of formula (1) is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the Working Examples.


Compounds of general formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of Formula (I). Those skilled in the art will recognize if a stereocenter exists in compounds of Formula (I). Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers as well. When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example,

Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).


Compounds of Formula I can be prepared according to the synthetic sequences illustrated in Schemes 1, 2, 3 and 4 and further detailed in the Examples section following.

Scheme 1

Compounds of Formula (1) may be prepared from Intermediates of Formula 5 either directly as in Scheme 1 below, or indirectly as in Scheme 2 below. In all the schemes below, each intermediate type is labelled by a number 1 - 11. For convenience, intermediates having these formulae are identified by these numerals in the specific examples section below.




Scheme 2




In an alternative method, compounds of Formula (1) wherein R^1 represents -3-hydroxyphenyl may be prepared according to Scheme 3 below:

Scheme 3



In a further method, when R^2 is 3-amino phenyl or a phenyl group substituted by NHCOCH_3 or similar amine derivative and R^1 is 3-hydroxyphenyl, Scheme 4 may be employed:

Scheme 4



Certain embodiments of the present invention will now be illustrated by way of example only. The physical data given for the compounds exemplified is consistent with the assigned structure of those compounds.

EXAMPLES

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature; for example, the *Journal of the American Chemical Society* or the *Journal of Biological Chemistry*. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used

without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:

	g (grams);	mg (milligrams);
	L (liters);	mL (milliliters);
5	μL (microliters);	psi (pounds per square inch);
	M (molar);	mM (millimolar);
	i. v. (intravenous);	Hz (Hertz);
	MHz (megahertz);	mol (moles);
	mmol (millimoles);	rt (room temperature);
10	min (minutes);	h (hours);
	mp (melting point);	TLC (thin layer chromatography);
	T _r (retention time);	RP (reverse phase);
	MeOH (methanol);	<i>i</i> -PrOH (isopropanol);
	TEA (triethylamine);	TFA (trifluoroacetic acid);
15	TFAA (trifluoroacetic anhydride);	THF (tetrahydrofuran);
	DMSO (dimethylsulfoxide);	AcOEt (ethyl acetate);
	DME (1,2-dimethoxyethane);	DCM (dichloromethane);
	DCE (dichloroethane);	DMF (<i>N,N</i> -dimethylformamide);
	DMPU (<i>N,N'</i> -dimethylpropyleneurea);	CDI (1,1-carbonyldiimidazole);
20	IBCF (isobutyl chloroformate);	HOAc (acetic acid);
	HOSu (<i>N</i> -hydroxysuccinimide);	HOBT (1-hydroxybenzotriazole);
	mCPBA (meta-chloroperbenzoic acid);	
	EDC (1-[3-dimethylamino] propyl]-3-ethylcarbodiimide hydrochloride);	
	BOC (<i>tert</i> -butoxycarbonyl);	FMOC (9-fluorenylmethoxycarbonyl); DCC
25	(dicyclohexylcarbodiimide);	CBZ (benzyloxycarbonyl);
	Ac (acetyl);	atm (atmosphere);
	TMSE (2-(trimethylsilyl)ethyl);	TMS (trimethylsilyl);
	TIPS (triisopropylsilyl);	TBS (<i>t</i> -butyldimethylsilyl);
	DMAP (4-dimethylaminopyridine);	BSA (bovine serum albumin)
30	ATP (adenosine triphosphate);	HRP (horseradish peroxidase);
	DMEM (Dulbecco's modified Eagle medium);	
	HPLC (high pressure liquid chromatography);	
	BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);	

TBAF (tetra-*n*-butylammonium fluoride);

HBTU (O-Benzotriazole-1-yl-N,N,N',N'-tetramethyluroniumhexafluoro phosphate).

HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid);

DPPA (diphenylphosphoryl azide);

5 fHNO₃ (fuming HNO₃); and

EDTA (ethylenediaminetetraacetic acid).

All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade).

10 All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted.

¹H NMR spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, a Brücker AVANCE-400, or a General Electric QE-300. Chemical shifts are
15 expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad).

HPLC were recorded on a Gilson HPLC or Shimazu HPLC system by the following conditions:
20 Column: 50 X 4.6mm (id) stainless steel packed with 5µm Phenomenex Luna C-18 ; Flow rate: 2.0 mL/min; Mobile phase: A phase = 50mM ammonium acetate (pH 7.4), B phase = acetonitrile, 0-0.5min (A: 100%, B: 0%), 0.5-3.0 min (A:100-0%, B:0-100%), 3.0-3.5min (A: 0%, B: 100%), 3.5-3.7 min (A: 0-100%, B: 100-0%), 3.7-4.5 min (A: 100%, B: 0%); Detection.: UV 254nm; Injection volume: 3µL.

25

Low-resolution mass spectra (MS) were recorded on a JOEL JMS-AX505HA, JOEL SX-102, or a SCIEX-APIiii spectrometer; LC-MS were recorded on a micromass 2MD and Waters 2690; high resolution MS were obtained using a JOEL SX-102A spectrometer. All mass spectra were taken under electrospray ionization (ESI), chemical ionization (CI), electron impact (EI)
30 or by fast atom bombardment (FAB) methods. Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1-mm NaCl cell. Most of the reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254),

visualized with UV light, 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution.

Flash column chromatography was performed on silica gel (230–400 mesh, Merck).

5 Example 1.

5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline

a. 5-Bromoisoquinoline (2)

To a suspension of AlCl_3 (156.7 g, 1.18 mol) in CH_2Cl_2 (500 mL), a solution of isoquinoline (1) (605 mmol, 71 mL) in CH_2Cl_2 (100 mL) was dropwise added at such rate that the reaction mixture was refluxed gently. After addition, CH_2Cl_2 was removed by distillation. The blackish residue was melted at 120°C then the temperature was adjusted to 100°C . To the mixture, Br_2 (31 mL, 605 mmol) was dropwise added over 2 hrs at 100°C and stirred for 30 min at same temperature, then was stirred at 75°C overnight. The mixture was cooled to room temperature then carefully poured into ice-water. The aqueous mixture was basified with NaOH aq. and extracted with ether. The organic layer was dried over Na_2SO_4 then evaporated. Sequence purification on SiO_2 column chromatography twice and recrystallization from hexane gave the title compound (34.5 g, 28 %). MS (ESI) $(\text{M}+\text{H})^+$ 208, 210.

b. 5-Bromoisoquinoline N-oxide (3)


To a solution of 5-bromoisoquinoline (2) (20.8 g, 100 mmol) in CH_2Cl_2 (500 mL), mCPBA (80 % assay, 23.7 g, 110 mmol) was added and stirred at 45°C overnight. After cooling, the mixture was quenched with $\text{Na}_2\text{S}_2\text{O}_3$ then extracted with CH_2Cl_2 . The organic layer was washed with NaOH aq. , dried over Na_2SO_4 then evaporated. Sequence recrystallization from CH_2Cl_2 -ether gave the title compound (20.1 g, 90 %). MS (ESI) $(\text{M}+\text{H})^+$ 224, 226.

c. 5-Bromo-1-chloroisoquinoline (4)

To a solution of 5-bromoisoquinoline N-oxide (3) (20.1 g, 89.5 mmol) in CH_2Cl_2 (500 mL), POCl_3 (20 mL, 215 mmol) was added and stirred at 45°C overnight. After cooling, the mixture was evaporated to remove POCl_3 then added water. The mixture was extracted with CH_2Cl_2 . The organic layer was washed with $\text{NaHCO}_3 \text{ aq.}$, dried over Na_2SO_4 then evaporated. Formed solid was washed with MeOH to give the title compound (16.1 g, 74 %). MS (ESI) $(\text{M}+\text{H})^+$ 242, 244, 246.

d. 5-Bromo-1-(quinolin-6-yl)aminoisoquinoline (5)


To a suspension of 5-bromo-1-chloroisoquinoline (4) (3.0 g, 12.4 mmol) in iPrOH (100 mL), 6-aminoquinoline (4.5 g, 31.2 mmol), 4M HCl-dioxane (5 mL) and MeOH (15 mL) were added and stirred at 80°C for 3 days. After cooling, the mixture was evaporated to remove solvent then suspended into AcOEt. The mixture was basified with NaHCO₃ aq; then-formed precipitate was collected by filtration and washed with AcOEt to give the title compound (5) (3.4 g, 78 %). MS (ESI) (M+H)⁺ 350, 352.

e. 5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline

A mixture of 5-bromo-1-(quinolin-6-yl)aminoisoquinoline (5) (70.0 mg, 0.2 mmol), Pd(PPh₃)₄ (11.6 mg, 5 mol%) and 5-indole boronic acid (36.5 mg, 0.24 mmol) was flushed N₂ gas then added dioxane (2 mL), ethanol (0.4 mL) and 2M K₂CO₃ aq (2 mL). The mixture was stirred at 85°C overnight. After cooling, the mixture was purified on SCX SPE then SiO₂ column chromatography. Formed solid was washed with MeOH to give the title compound (39.9 mg, 52%).

¹H-NMR (400 MHz, d₆-DMSO) δ 11.26(s, 1H), 9.57(s, 1H), 8.74(dd, 1H), 8.61(m, 2H), 8.26(dd, 1H), 8.20(dd, 1H), 8.04(d, 1H), 7.97(d, 1H), 7.72(m, 2H), 7.64(s, 1H), 7.55(d, 1H), 7.45(m, 2H), 7.20(m, 2H) and 6.52(m, 1H); MS (ESI) (M+H)⁺ 387.

Example 2.5-(2-Methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline




The title compound was prepared from 5-bromo-1-(quinolin-6-yl)aminoisoquinoline (5) and 2-methoxy-5-pyridine boronic acid as described in Example 1e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.63(br, 1H), 8.75(dd, 1H), 8.67(d, 1H), 8.61(d, 1H), 8.29(d, 1H), 8.27(d, 1H), 8.19(dd, 1H), 8.09(d, 1H), 7.98(d, 1H), 7.88(dd, 1H), 7.76(dd, 1H), 7.72(dd, 1H), 7.47(dd, 1H), 7.06(d, 1H), 7.01(d, 1H) and 3.95(s, 3H); MS (ESI) (M+H)⁺ 379.

Example 3.

5-(Pyridin-2-on-5-yl)-1-(quinolin-6-yl)aminoisoquinoline




A mixture of 5-(2-methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline (85.3 mg, 0.225 mmol) in conc.HCl aq. (30 mL) was stirred at 50°C for 3days then at 100°C for 1day. The mixture was evaporated to remove solvent. The residue was passed through NH₂-SPE then purified on SCX SPE. Formed solid was washed with CH₂Cl₂-MeOH to give the title compound (51.9 mg, 63%).

¹H-NMR (400 MHz, d₆-DMSO) δ 11.82(br, 1H), 9.59(s, 1H), 8.75(dd, 1H), 8.62(m, 2H), 8.27(d, 1H), 8.19(dd, 1H), 8.11(d, 1H), 7.97(d, 1H), 7.69(m, 2H), 7.60(dd, 1H), 7.52(br, 1H), 7.46(dd, 1H), 7.13(d, 1H) and 6.49(d, 1H); MS (ESI) (M+H)⁺ 365.

Example 4.

5-(4-Methoxymethoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline




The title compound was prepared from 5-bromo-1-(quinolin-6-yl)aminoisoquinoline (5) and 4-methoxymethoxyphenyl boronic acid as described in Example 1e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.59(br, 1H), 8.74(dd, 1H), 8.64(br, 1H), 8.61(d, 1H), 8.27(brd, 1H), 8.19(dd, 1H), 8.07(d, 1H), 7.97(d, 1H), 7.73(dd, 1H), 7.67(dd, 1H), 7.48-7.43(m, 3H), 7.20(d, 2H), 7.13(d, 1H), 5.29(s, 2H) and 3.44(s, 3H); MS (ESI) (M+H)⁺ 408.

Example 5.

5-(4-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline



A mixture of 5-(4-Methoxymethoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline (68.6 mg, 0.168 mmol) and sat. HCl-MeOH (2mL) in MeOH (12mL) and water (2mL) was stirred at 50°C for 3days. The mixture was evaporated to remove solvent. The residue was passed through NH₂-SPE then purified on SCX SPE. Formed solid was washed with ether to give the title compound (18.4 mg, 30%).

¹H-NMR (400 MHz, d₆-DMSO) δ 9.56(s, 1H), 8.74(dd, 1H), 8.59(m, 2H), 8.26(d, 1H), 8.19(dd, 1H), 8.06(d, 1H), 7.97(d, 1H), 7.70(dd, 1H), 7.62(d, 1H), 7.45(dd, 1H), 7.30(d, 2H), 7.16(d, 1H) and 6.93(d, 2H) (1H not detected); MS (ESI) (M+H)⁺ 364.


Example 6.

5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline

a. 5-(4-Benzoyloxy-3-fluorophenyl)-1-(quinolin-6-yl)aminoisoquinoline

The title compound was prepared from 5-bromo-1-(quinolin-6-yl)aminoisoquinoline (5) and 4-benzyloxy-3-fluorophenyl boronic acid as described in Example 1e. MS (ESI) (M+H)⁺ 472.

5 b. 5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline



To a mixture of 5-(4-benzyloxy-3-fluorophenyl)-1-(quinolin-6-yl)aminoisoquinoline (116.9 mg, 0.248 mmol) in CH₂Cl₂ (10 mL), BBr₃ in CH₂Cl₂ (1.0M solution, 2.5 mL) was added at -78°C and was stirred at -78°C for 3hrs then at room temperature overnight. The reaction was quenched with methanol then evaporated to remove solvent. The residue was passed through NH₂-SPE then purified on SCX SPE. Formed solid was washed with methanol and ether to give the title compound (57.1 mg, 60%).

¹H-NMR (400 MHz, d₆-DMSO) δ 10.07(br, 1H), 9.58(s, 1H), 8.74(dd, 1H), 8.61(m, 2H), 8.27(d, 1H), 8.19(dd, 1H), 8.08(d, 1H), 7.97(d, 1H), 7.71(dd, 1H), 7.66(d, 1H), 7.46(dd, 1H), 7.29(dd, 1H) and 7.16-7.11(m, 3H); MS (ESI) (M+H)⁺ 382.


Example 7.

1-Amino-5-(indol-5-yl)isoquinoline

20 a. 1-Amino-5-bromoisoquinoline (5)

A suspension of 5-bromo-1-chloroisoquinoline (4) (2.0 g, 8.25 mmol) in sat. NH₃-MeOH (100 mL) was heated to 180°C for 15days in an autoclave. After cooling, the solvent was removed by evaporation. The residue was washed with CH₂Cl₂ then purified on SCX SPE. Formed solid was washed with hexane to give the title compound (1.57 g, 85 %). MS (ESI) (M+H)⁺ 223, 225.

b. 1-Amino-5-(indol-5-yl)isoquinoline




The title compound was prepared from 1-Amino-5-bromoisoquinoline (5) and 5-indole boronic acid as described in Example 1e.

¹H-NMR (400 MHz, d₆-DMSO) δ 11.21(br, 1H), 8.17(d, 1H), 7.73(d, 1H), 7.57(br, 1H), 7.55(dd, 1H), 7.52-7.49(m, 2H), 7.42(dd, 1H), 7.15(dd, 1H), 6.85(d, 1H), 6.78(br, 2H) and 6.49(m, 1H);

MS (ESI) (M+H)⁺ 260.

Example 8.

1-Amino-5-(2-methoxypyridin-5-yl)isoquinoline




The title compound was prepared from 1-amino-5-bromoisoquinoline (5) and 2-methoxy-5-pyridine boronic acid as described in Example 1e.

¹H-NMR (400 MHz, d₆-DMSO) δ 8.23(m, 2H), 7.80(dd, 1H), 7.78(d, 1H), 7.54(m, 2H), 6.96(d, 1H), 6.87(br, 2H), 6.70(d, 1H) and 3.93(s, 3H); MS (ESI) (M+H)⁺ 252.

Example 9.

1-Amino-5-(pyridin-2-on-5-yl)isoquinoline




The title compound was prepared from 1-amino-5-(2-methoxypyridin-5-yl)isoquinoline as described in Example 3.

¹H-NMR (400 MHz, d₆-DMSO) δ 11.80(br, 1H), 8.19(d, 1H), 7.79(d, 1H), 7.56–7.43(m, 4H), 6.85(br, 2H), 6.76(d, 1H) and 6.45(d, 1H); MS (ESI) (M+H)⁺ 238.

Example 10.

5-1-Amino-5-(3-methoxyphenyl)isoquinoline



The title compound was prepared from 1-amino-5-bromoisquinoline (5) and 3-methoxyphenyl boronic acid as described in Example 1e.

¹H-NMR (400 MHz, d₆-DMSO) δ 8.21(d, 1H), 7.76(d, 1H), 7.53(m, 2H), 7.42(dd, 1H), 7.03–6.95(m, 3H), 6.84(br, 2H), 6.78(d, 1H) and 3.81(s, 3H); MS (ESI) (M+H)⁺ 251.


Example 11.

5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline

a. 1-(Quinolin-6-yl)amino-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinoline (6)

A mixture of 5-bromo-1-(quinolin-6-yl)aminoisoquinoline (5) (350 mg, 1.0 mmol), KOAc (490 mg, 5.0 mmol), PdCl₂(dppf)-CH₂Cl₂ (81.7 mg, 10 mol%) and bis(pinacolato)diboron (1.27 g, 5.0 mmol) was flushed N₂ gas then added DMF (8 mL). The mixture was stirred at 80°C overnight. After cooling, the mixture was purified on SCX SPE to give title compound. (MS (ESI) (M+H)⁺ 398.

b. 5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline




A mixture of 1-(quinolin-6-yl)amino-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinoline (6) (37.8 mg, 0.1 mmol), Pd(PPh₃)₄ (6.0 mg, 5 mol%) and 2-hydroxy-6-

bromonaphthalene (27 mg, 0.12 mmol) was flushed N₂ gas then added dioxane (1.5 mL), ethanol (0.3 mL) and 2M K₂CO₃aq (1.5 mL). The mixture was stirred at 90°C overnight. After cooling, the mixture was purified on SCX SPE, SiO₂ column chromatography then NH₂ SPE. Formed solid was washed with MeOH to give the title compound (9.5 mg, 23%).

¹H-NMR (400 MHz, d₆-DMSO) δ 9.89(br, 1H), 9.62(s, 1H), 9.75(dd, 1H), 8.67(dd, 1H), 8.62(d, 1H), 8.27(d, 1H), 8.21(dd, 1H), 8.08(d, 1H), 7.98(d, 1H), 7.91(s, 1H), 7.88(d, 1H), 7.85(d, 1H), 7.76(m, 2H), 7.52(dd, 1H), 7.47(dd, 1H), 7.23(d, 1H) and 7.16(m, 2H); MS (ESI) (M+H)⁺ 414.

Example 12.

10 5-(4-Chloro-3-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline




The title compound was prepared from 1-(quinolin-6-yl)amino-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinoline (6) and 5-bromo-2-chlorophenol as described in

15 Example 11b.

¹H-NMR (400 MHz, d₆-DMSO) δ 10.45(br, 1H), 9.61(s, 1H), 8.75(dd, 1H), 8.65(d, 1H), 8.61(d, 1H), 8.27(d, 1H), 8.19(dd, 1H), 8.08(d, 1H), 7.98(d, 1H), 7.73(dd, 1H), 7.66(d, 1H), 7.47(m, 2H), 7.13(d, 1H), 7.76(d, 1H) and 6.91(dd, 1H); MS (ESI) (M+H)⁺ 398.

20 Example 13.

3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide



a: 3-(5-Bromoisoquinulin-1-ylamino)benzenesulfonamide (5)

The title compound was prepared from 5-bromo-1-chloroisoquinoline (4) and 3-aminobenzenesulfonamide as described in Example 1d. MS (ESI) (M+H)⁺ 378, 380.

5 b. 3-[5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinolin-1-ylamino]benzenesulfonamide (6)

The title compound was prepared from 3-(5-bromoisoquinolin-1-ylamino)benzenesulfonamide (5) as described in Example 11a. MS (ESI) (M-H)⁻ 342 (as boronic acid).


10 c. 3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide

The title compound was prepared from 3-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-isoquinolin-1-ylamino]benzenesulfonamide (6) and 5-bromo-2-chlorophenol as described in Example 11b.

15 ¹H-NMR (400 MHz, d₆-DMSO) δ 10.38(br, 1H), 9.57(s, 1H), 8.60 (d, 1H), 8.43(dd, 1H), 8.13(d, 1H), 8.02(d, 1H), 7.71(dd, 1H), 7.65(d, 1H), 7.52(dd, 1H), 7.48(dd, 1H), 7.45(d, 1H), 7.35(br, 2H), 7.11(d, 1H), 7.04(d, 1H) and 6.89(dd, 1H); MS (ESI) (M+H)⁺ 426.

Example 14.

20 5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline



a. 5-(3-Benzyloxyphenyl)isoquinoline (7)

The title compound was prepared from 5-bromoisoquinoline (2) and 3-benzyloxyphenylboronic acid as described in Example 1e. MS (ESI) (M+H)⁺ 312.

25

b. 5-(3-Benzyloxyphenyl)isoquinoline N-oxide (8)

The title compound was prepared from 5-(3-benzyloxyphenyl)isoquinoline (7) as described in Example 1b. MS (ESI) (M+H)⁺ 328.

c. 5-(3-Benzyloxyphenyl)-1-chloroisoquinoline (9)

The title compound was prepared from 5-(3-benzyloxyphenyl)isoquinoline N-oxide (8) as described in Example 1c. MS (ESI) (M+H)⁺ 346.

d. 5-(3-Benzyloxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline (10)

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 4-trifluoromethylaniline as described in Example 1d. MS (ESI) (M+H)⁺ 471.


e. 5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline

A mixture of 5-(3-benzyloxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline (10) (78.4 mg, 0.167 mmol), catalytic amount of 5%Pd-C in methanol (10 mL) was stirred vigorously under hydrogen atmosphere at room temperature for 4days. The mixture was purified on SCX SPE, SiO₂ column chromatography. Formed solid was washed with ether-hexane to give the title compound (29.1 mg, 46%).

¹H-NMR (400 MHz, d₆-DMSO) δ 9.66(br, 1H), 9.61(s, 1H), 8.58(d, 1H), 8.13(d, 1H), 8.05(d, 1H), 7.72(dd, 1H), 7.68-7.65(m, 3H), 7.34(dd, 1H), 7.17(d, 1H) 6.89(d, 1H) and 6.86(m, 2H); MS (ESI) (M+H)⁺ 381.


Example 15.

5-(3-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline



The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 6-aminoquinoline as described in Example 14d and 14e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.66(br, 1H), 9.59(s, 1H), 8.75(dd, 1H), 8.64(d, 1H), 8.61(d, 1H), 8.27(dd, 1H), 8.19(dd, 1H), 8.08(d, 1H), 7.97(d, 1H), 7.72(dd, 1H), 7.66(d, 1H), 7.47(dd, 1H), 7.34(dd, 1H), 7.15(d, 1H) and 6.90-6.86(m, 3H); MS (ESI) (M+H)⁺ 364.


Example 16.**1-(4-Aminocarbonylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline**

5

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 4-aminobenzene carboxamide as described in Example 14d and 14e.

$^1\text{H-NMR}$ (400 MHz, $\text{d}_6\text{-DMSO}$) δ 9.64(s, 1H), 9.50(br, 1H), 8.57(d, 1H), 8.03(d, 1H), 7.97(d, 2H), 7.86(d, 2H), 7.83(br, 1H), 7.71(dd, 1H), 7.65(d, 1H), 7.33(dd, 1H), 7.19(br, 1H), 7.13(d, 1H) and 6.89-6.85(m, 3H); MS (ESI) $(\text{M}+\text{H})^+$ 356.

10

Example 17.**5-(3-Hydroxyphenyl)-1-[4-(imidazol-1-yl)phenyl]aminoisoquinoline**


15

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 4-(1-imidazolyl)aniline as described in Example 14d and 14e.

$^1\text{H-NMR}$ (400 MHz, $\text{d}_6\text{-DMSO}$) δ 9.65(br, 1H), 9.40(s, 1H), 8.57(d, 1H), 8.19(s, 1H), 8.03(d, 2H), 7.99(d, 1H), 7.70(m, 2H), 7.64(d, 1H), 7.60(d, 2H), 7.33(dd, 1H), 7.09(m, 2H) and 6.88-6.84(m, 3H); MS (ESI) $(\text{M}+\text{H})^+$ 379.

20

Example 18.**3-[5-(3-Hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide**




The title compound was prepared from 5-(3-benzoylsulfonylphenyl)-1-chloroisoquinoline (9) and 3-aminobenzene sulfonamide as described in Example 14d and 14e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.55(br, 1H), 9.55(s, 1H), 8.58(d, 1H), 8.44(dd, 1H), 8.13(dd, 1H), 8.01 (dd, 1H), 7.70(dd, 1H), 7.64(d, 1H), 7.51(dd, 1H), 7.44(m, 1H), 7.34 (m, 3H), 7.12(d, 1H) and 6.88-6.84(m, 3H); MS (ESI) (M+H)⁺ 392.

Example 19.

5-(3-Hydroxyphenyl)-1-(3-methoxyphenyl)aminoisoquinoline




The title compound was prepared from 5-(3-benzoylsulfonylphenyl)-1-chloroisoquinoline (9) and 3-methoxyaniline as described in Example 14d and 14e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.63(br, 1H), 9.20(s, 1H), 8.54(d, 1H), 7.98(d, 1H), 7.67(dd, 1H), 7.61(m, 2H), 7.50(dd, 1H), 7.32(dd, 1H), 7.22(dd, 1H), 7.06(d, 1H), 6.88-6.84(m, 3H), 6.58(dd, 1H) and 3.77(s, 3H); MS (ESI) (M+H)⁺ 343.

Example 20.

1-(3-Ethylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline




The title compound was prepared from 5-(3-benzoylsulfonylphenyl)-1-chloroisoquinoline (9) and 3-ethylaniline as described in Example 14d and 14e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.63(br, 1H), 9.16(s, 1H), 8.55(d, 1H), 7.95(d, 1H), 7.74(d, 1H), 7.67(d, 1H), 7.65(d, 1H), 7.61(d, 1H), 7.32(dd, 1H), 7.23 (dd, 1H), 7.03(d, 1H), 6.87-6.84(m, 4H), 2.62(q, 2H) and 1.22(t, 3H); MS (ESI) (M+H)⁺ 341

5 Example 21:

N-(2-Diethylaminoethyl)-4-[5-(3-hydroxyphenyl)isoquinolin-1-ylamino]benzamide.




The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and procainamide hydrochloride as described in Example 14d and 14e.

10 ¹H-NMR (400 MHz, d₆-DMSO) δ 9.65(br, 1H), 9.46(s, 1H), 8.57(d, 1H), 8.21(dd, 1H), 8.03(d, 1H), 7.97(d, 2H), 7.81(d, 2H), 7.71(dd, 1H), 7.64(d, 1H), 7.33(dd, 1H), 7.13(d, 1H), 6.88-6.85(m, 3H) and 0.98(t, 6H) (2H overlapped with H₂O, 6H overlapped with DMSO); MS (ESI) (M+H)⁺ 455.


15 Example 22.

1-(3-(4-Aminophenoxy)phenyl)amino-5-(3-hydroxyphenyl)isoquinoline



The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 3-(4-nitrophenoxy)aniline as described in 14d and 14e.

20 ¹H-NMR (400 MHz, d₆-DMSO) δ 9.63(br, 1H), 9.23(s, 1H), 8.51(d, 1H), 7.95(d, 1H), 7.65(dd, 1H), 7.60(m, 2H), 7.51(dd, 1H), 7.32(dd, 1H), 7.21(dd, 1H), 7.05(d, 1H), 6.85(m, 3H), 6.80(d, 2H), 6.60(d, 2H), 6.47(dd, 1H) and 4.96(br, 2H); MS (ESI) (M+H)⁺ 420.


Example 23.5-(3-Hydroxyphenyl)-1-phenylaminoisoquinoline

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and

5 aniline as described in Example 14d and 14e.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.63(br, 1H), 9.22(s, 1H), 8.55(d, 1H), 7.96(d, 1H), 7.87(d, 2H), 7.67(dd, 1H), 7.62(d, 1H), 7.32(m, 3H), 7.5(d, 1H), 7.00(m, 1H) and 6.88-6.84(m, 3H);

MS (ESI) (M+H)⁺ 312.


10 Example 24.5-(3-Hydroxyphenyl)-1-(3,4-methylenedioxyphenyl)aminoisoquinoline

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 3,4-methylenedioxyaniline as described in Example 14d and 14e.

15 ¹H-NMR (400 MHz, d₆-DMSO) δ 9.62(br, 1H), 9.12(s, 1H), 8.50(d, 1H), 7.91(d, 1H), 7.65(dd, 1H), 7.60(d, 1H), 7.54(d, 1H), 7.32(dd, 1H), 7.23(dd, 1H), 7.00(d, 1H), 6.89(d, 1H), 6.87-6.82(m, 3H) and 6.00(s, 2H); MS (ESI) (M+H)⁺ 357.


Example 25.20 1-Amino-5-(3-hydroxyphenyl)isoquinolinea. 1-Amino-5-(3-benzyloxyphenyl)isoquinoline (10)

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) as described in Example 7a. MS (ESI) (M+H)⁺ 327.

b. 1-Amino-5-(3-hydroxyphenyl)isoquinoline

To a mixture of 1-amino-5-(3-benzyloxyphenyl)isoquinoline (10) (54.5 mg, 0.167 mmol) in CH₂Cl₂ (2 mL), BBr₃ in CH₂Cl₂ (1.0M solution, 1.7 mL) was added at -78°C and stirred at -78°C for 10 min. The temperature was gradually risen to ambient temperature then stirred at room temperature overnight. The reaction was quenched with methanol then evaporated to remove solvent. The residue was purified on SCX SPE. Formed solid was washed with MeOH to give the title compound (21.4 mg, 54%).


¹H-NMR (400 MHz, d₆-DMSO) δ 9.58(br, 1H), 8.27(dd, 1H), 7.75(d, 1H), 7.50(m, 2H), 7.29(dd, 1H) and 6.84–6.78(m, 6H); MS (ESI) (M+H)⁺ 237.

Example 26.1-(Benzothiazol-6-yl)amino-5-(3-hydroxyphenyl)isoquinoline

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 6-aminobenzothiazole as described in Example 14d and sequence deprotection as described in 25b.

¹H-NMR (400 MHz, d₆-DMSO) δ 9.64(s, 1H), 9.50(s, 1H), 9.23(s, 1H), 8.84(d, 1H), 8.60(d, 1H), 8.03(m, 2H), 7.93(dd, 1H), 7.71(dd, 1H), 7.64(d, 1H), 7.33(dd, 1H), 7.11(d, 1H) and 6.90–6.85(m, 3H); MS (ESI) (M+H)⁺ 370.

Example 27.1-(Benzimidazol-5-yl)amino-5-(3-hydroxyphenyl)isoquinoline



The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 5-aminobenzimidazole as described in Example 14d and sequence deprotection as described in 25b.

- 5 $^1\text{H-NMR}$ (400 MHz, d_6 -DMSO) δ 12.30(br, 1H), 9.63(br, 1H), 9.24(br, 1H), 8.58(brd, 1H), 8.30-8.12(br, 2H), 7.94(br, 1H), 7.66(dd, 1H), 7.61-7.50(br, 3H), 7.32(dd, 1H), 7.01(br, 1H) and 6.88-6.83(m, 3H); MS (ESI) $(\text{M}+\text{H})^+$ 353.

Example 28.

10 1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline

a. 5-(3-Benzyloxyphenyl)-1-(3-nitrophenyl)aminoisoquinoline (10)

The title compound was prepared from 5-(3-benzyloxyphenyl)-1-chloroisoquinoline (9) and 3-nitroaniline as described in Example 14d. MS (ESI) $(\text{M}+\text{H})^+$ 448.


15

b. 1-(3-Aminophenyl)amino-5-(3-benzyloxyphenyl)isoquinoline (11)

To a solution of 5-(3-benzyloxyphenyl)-1-(3-nitrophenyl)aminoisoquinoline (10) (213.3 mg, 0.477 mmol) in AcOH (10 mL), Zn powder (300 mg) was added and stirred at room temperature for 1.5hr. The mixture was evaporated to remove solvent. The residue was


20 purified on SCX SPE and NH₂ SPE. Sequence crystallization from ether gave the title compound (133.8 mg, 67%). MS (ESI) $(\text{M}+\text{H})^+$ 418.

c. 1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline




The title compound was prepared from 1-(3-aminophenyl)amino-5-(3-benzyloxyphenyl)isoquinoline (11) as described in 25b.

$^1\text{H-NMR}$ (400 MHz, $\text{d}_6\text{-DMSO}$) δ 9.64(br, 1H), 8.94(s, 1H), 8.52(dd, 1H), 7.92(d, 1H), 7.63(dd, 1H), 7.59(dd, 1H), 7.32(dd, 1H), 7.16(s, 1H), 7.00(d, 1H), 6.95(m, 2H), 6.87-6.83(m, 3H), 6.24(m, 1H) and 4.98(d, 2H); MS (ESI) $(\text{M}+\text{H})^+$ 328.





Example 29.

{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}urea



To a mixture of 1-(3-aminophenyl)amino-5-(3-benzyloxyphenyl)isoquinoline (11) (41.8 mg, 0.1 mmol) in THF (1 mL), trimethylsilylisocyanate (14.9 μL , 0.11 mmol) was added and stirred at room temperature for 3 days. The mixture was passed through SCX-SPE to give a crude mixture of {3-[5-(3-benzyloxyphenyl)isoquinolin-1-ylamino]phenyl}urea. The crude mixture was treated with BBr_3 as described in 25b to give the title compound (18.5 mg, 50%).

$^1\text{H-NMR}$ (400 MHz, $\text{d}_6\text{-DMSO}$) δ 9.63(br, 1H), 9.17(s, 1H), 8.56(d, 1H), 8.48(s, 1H), 7.95(d, 1H), 7.89(dd, 1H), 7.65(dd, 1H), 7.60(d, 1H), 7.37(ddd, 1H), 7.32(dd, 1H), 7.14(m, 2H), 7.03(d, 1H), 6.90-6.84(m, 3H) and 5.82(br, 2H); MS (ESI) $(\text{M}+\text{H})^+$ 371.

**Example 30.****N-{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide**


- 5 To a mixture of 1-(3-aminophenyl)amino-5-(3-benzyloxyphenyl)isoquinoline (**11**) (41.8 mg, 0.1 mmol) in THF (1 mL), acetic anhydride (11.3 μ L, 0.12 mmol) was added at 0°C and stirred at room temperature for 3 days. The mixture was passed through SCX-SPE to give a crude mixture of N-{3-[5-(3-benzyloxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide. The crude mixture was treated with BBr₃ as described in 25b to give the title compound
- 10 (20.9 mg, 57%).

¹H-NMR (400 MHz, d₆-DMSO) δ 9.90(s, 1H), 9.64(s, 1H), 9.24(s, 1H), 8.56(d, 1H), 8.12(s, 1H), 7.96(d, 1H), 7.66(dd, 1H), 7.61(dd, 1H), 7.48(d, 1H), 7.32(dd, 1H), 7.26(d, 1H), 7.21(dd, 1H), 7.05(d, 1H), 6.88–6.84(m, 3H) and 2.05(s, 3H); MS (ESI) (M+H)⁺ 370.

15

BIOLOGICAL DATA**Alk5 Fluorescence Polarization Assay****Assay principle**

- 20 Kinase inhibitor compounds, conjugated to fluorophores, can be used as fluorescent ligands to monitor ATP competitive binding of other compounds to a given kinase. The increase in depolarization of plane polarized light, caused by release of the bound ligand into solution, is measured as a polarization/anisotropy value. This protocol details the use of the rhodamine green-labeled ligand depicted below



for assays using recombinant GST-ALK5 (residues 198-503). This ligand is derived from 5-
 [2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and
 5 rhodamine green according to the following protocol

Step 1. 4-Chloro-3,*N*-dimethoxy-*N*-methyl-benzamide

A suspension of 4-chloro-3-methoxybenzoic acid (F. Claudi *et al J. Med. Chem.*, 1992, 35,
 10 4408) (37.2g, 0.2mol) in dichloromethane (500ml) containing oxalyl chloride (26ml) was
 treated with *N,N*-dimethylformamide (10 drops). After stirring at room temperature for 6
 hours the solution was concentrated at reduced pressure, additional dichloromethane
 added to the residue and the solvent was re-evaporated. The residue was then dissolved in
 acetonitrile (600ml) and methoxymethylamine hydrochloride (20.5g, 0.21mol) added. The
 15 mixture was cooled in an ice-bath, a solution of pyridine (80ml) in acetonitrile (150ml)
 added dropwise and the mixture stirred at room temperature for 18 hours. The solution
 was then concentrated and the residue was partitioned between ethyl acetate and
 saturated potassium carbonate solution. The organic layer was separated, washed with
 brine, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced
 20 pressure, then the residue re-evaporated with toluene to give the title compound (40.0g,
 87%) as a colourless oil; MS(ES+) *m/e* 230/232 [M+H]⁺.

Step 2. 1-(4-Chloro-3-methoxyphenyl)-2-pyridin-4-yl-ethanone

4-Picoline (16.9ml, 0.174mol) was added dropwise to a stirred solution of lithium diisopropylamide (110ml, 0.22mol, 2M solution in heptane, ethylbenzene, tetrahydrofuran) in dry tetrahydrofuran (150ml) at -78°C . After stirring at -78°C for 15 min a solution of the product of Step 1 (40.0g, 0.174mol) in tetrahydrofuran (100ml) was added dropwise and the reaction allowed to warm to room temperature over 3 hours. The solution was then cooled in ice, saturated ammonium chloride solution added and the aqueous mixture extracted with ethyl acetate. The combined organic extracts were then washed with brine, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The resulting gum was triturated with cold diethyl ether/hexane (1:1, 300ml) and the solid collected to give the title compound as a pale yellow solid (29g, 64%); MS(ES+) m/e 262/264 $[\text{M}+\text{H}]^{+}$.

Step 3. 1-(4-Chloro-3-methoxy-phenyl)-2-pyridin-4-yl-ethane-1,2-dione

A solution of the product of Step 2 (22.5g, 86mmol) in dimethylsulphoxide (150ml) was stirred at 55°C . Hydrogen bromide (48% aqueous, 21ml) was added dropwise and the solution was heated at 55°C for 1 hour. After cooling to room temperature the solution was poured into a solution of sodium acetate (21g) in ice-water (1000ml) and the resulting slurry was stirred at room temperature for 30 minutes. The mixture was extracted with ethyl acetate and the organic layers were combined, washed with brine, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The residue was triturated with diethyl ether/hexane (1:4) and the solid collected to give the title compound as a yellow solid; MS(EI) m/e 275/277 $[\text{M}]^{+}$.

Step 4. 4-[4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-benzonitrile

The product of Step 3 (2.0g, 7.25mmol), 4-cyanobenzaldehyde (1.2g, 9.16mmol) and ammonium acetate (5.6g, 72.7mmol) were dissolved in glacial acetic acid (70ml), heated to reflux for 1 hour then allowed to cool to room temperature. The reaction mixture was then poured into a mixture of ammonium hydroxide and ice, and extracted into ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulphate, filtered and concentrated at reduced pressure. The residue was then purified by silica gel chromatography eluting with ethyl acetate to yield the title compound (1.23g, 44%); MS(ES+) m/e 387/389 $[\text{M}+\text{H}]^{+}$.

Step 5. 4-[4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1*H*-imidazol-2-yl]-benzylamine

The product of Step 4 (557mg, 1.44mmol) was dissolved in THF (60ml), treated with borane-dimethylsulphide complex (0.82ml, 8.64mmol) and heated to reflux for 4 hours. After cooling to room temperature, methanol (10ml) was added and the reaction mixture brought back to reflux for 30 minutes. The mixture was then concentrated under reduced pressure, treated with 2M hydrochloric acid and heated to reflux for a further 1 hour. After cooling to room temperature, the pH of the reaction mixture was adjusted to pH8 whereby the product precipitated. The precipitate was collected by filtration, washed with water and then dried over phosphorus pentoxide to give the title compound (560mg, 99%);

MS(ES+) m/e 391/393 [M+H]⁺.

Step 6. 5-[2-(4-Aminomethyl-phenyl)-5-pyridin-4-yl-1*H*-imidazol-4-yl]-2-chloro-phenol

A solution of the product of Step 5 (540mg, 1.38mmol) in dichloromethane (50ml) was cooled to 0°C and treated with boron tribromide (5.8ml, 1M solution in dichloromethane, 5.8mmol). After stirring at 0°C for 1 hour followed by 16 hours at room temperature, the mixture was treated with 2M hydrochloric acid (10ml) and then heated at 50°C for 30 minutes. After cooling to room temperature, the mixture was adjusted to pH 8 by the addition of aqueous sodium hydrogen carbonate solution and the resulting precipitate collected by filtration. The crude product was purified by silica gel chromatography eluting with chloroform/methanol/0.880 ammonia solution (60:40:4) to yield the title compound (242mg, 47%); MS(ES+) m/e 377/379 [M+H]⁺.

Step 7.

A solution of the product of Step 6 (40mg, 0.11mmol) was dissolved in dimethylformamide (3ml) and treated with Rhodamine Green succinic ester (40mg, 0.08mmol). The reaction mixture was stirred for 1 hour at room temperature and then concentrated at reduced pressure. The product was purified by reverse-phase column chromatography (tC18 Sep-Pak cartridge) eluting with acetonitrile/water (25:75) to yield the title compound (20mg, 34%); MS (ES-) m/e 731/733 [M-H]⁻.

Assay protocol

Assay buffer components: 62.5 mM Hepes pH 7.5 (Sigma H-4034), 1 mM DTT (Sigma D-0632), 12.5 mM MgCl₂ (Sigma M-9272), 1.25 mM CHAPS (Sigma C-3023).


5 ALK5 was added to assay buffer containing the above components and 1 nM of the fluorescent ligand described above so that the final ALK5 concentration is 10 nM based on active site titration of the enzyme. 40 µl of the enzyme/ligand reagent was added to each well of assay plates containing test compounds. A control compound (1 µl) was added to
10 column 21, rows A-P for the low control values. The plates were read immediately on a LJL Acquest fluorescence reader (Molecular Devices, serial number AQ1048) with excitation, emission, and dichroic filters of 485nm, 530 nm, and 505 nm, respectively. The fluorescence polarization for each well was calculated by the Acquest and is then imported into curve fitting software for construction of concentration response curves. The percent
15 inhibition of activity was calculated relative to high controls (C1, 1 µl DMSO in column 22, rows A-P) and low controls (C2, 1 µl of control compound in column 21, rows A-P) using, $100 \times (1 - (U1 - C2) / (C1 - C2))$. The concentration of test compound yielding 50% inhibition was determined using the equation, $y = ((V_{max} \times x) / (K + x)) + Y2$, where "K" was equal to the IC₅₀. The IC₅₀ values were converted to pIC₅₀ values, i.e., -log IC₅₀ in Molar concentration.

20 All the Exemplified Examples 1-30 were run with the above recited assay and showed inhibitory activity versus ALK5 with a pIC of 5.0 or greater.

25 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features described herein. This may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claims.

CLAIMS

1. A compound of Formula (I):



- 5 wherein R¹ represents a phenyl or naphthyl group (each of which is optionally substituted by one or more substituents selected from -OH, -C₁₋₆alkyl, C₁₋₆haloalkyl, -C₁₋₆alkoxy, -halogen, or a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by -C₁₋₆alkoxy, -C₁₋₆alkyl, C₁₋₆haloalkyl or =O;
- 10 R² represents H, phenyl (optionally substituted by -NR³R⁴, -C₁₋₄alkoxy, -C₁₋₆alkyl, -CONR³R⁴, -SO₂NR³R⁴, -NHCONR³R⁴, -NHCOC₁₋₆alkyl, -C₁₋₆haloalkyl, -OCH₂-O, -phenoxy (wherein the phenyl moiety is optionally substituted by NH₂, -C₁₋₃alkyl, -C₁₋₃alkoxy, -CF₃, -5 membered heteroaryl group comprising one or two nitrogen atoms), a -benzimidazolyl, a-benzothiazolyl, or an -isoquinoliny, or quinoliny group.
- 15 R³ and R⁴ are independently selected from H, -C₁₋₆alkyl, -C₁₋₃alkylNR⁵R⁶
- R⁵ and R⁶ are independently H or C₁₋₃alkyl.
- 20 or a salt, solvate, or physiologically functional derivative thereof:
2. A compound according to claim 1 wherein R¹ phenyl (optionally substituted by one or more substituents selected from -OCH₂OCH₃, -OH, -halogen, -OCH₃), naphthyl (substituted by OH), indoliny, quinoliny or a pyridiny moiety (wherein the pyridiny moiety
- 25 is optionally substituted by -OCH₃ or = O).
3. A compound according to claim 2 wherein R¹ is phenyl substituted by OH.

4. A compound according to claim 3 wherein the OH is on the 5 position of the phenyl ring.

5. A compound according to claims 1 – 4 wherein R² is H, quinoline, phenyl (optionally substituted by -SO₂NH₂, CF₃, -CONH₂, -imidazolyl, -OCH₃, C₁₋₃ alkyl, -OCH₂O-, CONH-CH₂CH₂N(CH₂CH₃), -O-phenyl (where the phenyl is substituted by NH₂), -NHCOCH₃, NH₂, NHCOCH₃), or benzoimidazolyl or benzothiazolyl moiety.

6. A compound according to claim 5 where in R² is a quinoline moiety, a quinoline 6-yl moiety.

7. A compound according to claim 6 wherein R² is a quinoline 6-yl moiety.

8. A compound as claimed in claim 1, selected from the group consisting of:

- 5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(2-Methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(Pyridin-2-on-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(4-Methoxymethoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(4-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
- 1-Amino-5-(indol-5-yl)isoquinoline;
- 1-Amino-5-(2-methoxypyridin-5-yl)isoquinoline;
- 1-Amino-5-(pyridin-2-on-5-yl)isoquinoline;
- 1-Amino-5-(3-methoxyphenyl)isoquinoline;
- 5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline;
- 5-(4-Chloro-3-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
- 3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;
- 5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline;
- 5-(3-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
- 1-(4-Aminocarbonylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
- 5-(3-Hydroxyphenyl)-1-[4-(imidazol-1-yl)phenyl]aminoisoquinoline;
- 3-[5-(3-Hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(3-methoxyphenyl)aminoisoquinoline;
1-(3-Ethylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
N-(2-Diethylaminoethyl)-4-[5-(3-hydroxyphenyl)isoquinolin-1-ylamino]benzamide;
1-(3-(4-Aminophenoxy)phenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
5-(3-Hydroxyphenyl)-1-phenylaminoisoquinoline;
5-(3-Hydroxyphenyl)-1-(3,4-methylenedioxyphenyl)aminoisoquinoline;
1-Amino-5-(3-hydroxyphenyl)isoquinoline;
1-(Benzothiazol-6-yl)amino-5-(3-hydroxyphenyl)isoquinoline
1-(Benzimidazol-5-yl)amino-5-(3-hydroxyphenyl)isoquinoline
1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline
{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}urea
N-{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide;

or a salt, solvate, or physiologically functional derivative thereof.

15

9. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

20

10. A compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.


25

11. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate ALK5 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof.

30

12. Use of a compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate ALK5 activity.

13. A method according to claim 11 wherein the disorder mediated by inappropriate ALK5 activity is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.
- 10 14. Use according to claim 12 wherein the disorder mediated by inappropriate ALK5 activity is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.
- 15



PCT/EP2004/013072



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.